Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
TO - ALLERGEN EXTRACT VACCINE is a federal award for W40m Mrco East held by Greer Laboratories, Inc. Estimated value $261K ($261K obligated). Current period of performance ends Jun 30, 2023. Place of performance: FORT GEORGE G MEADE MD.
Recompete timing
PublicCurrent PoP ended Jun 30, 2023 (1148 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W91YTZ23F0184?
W91YTZ23F0184 (- allergen extract vaccine) is a W40m Mrco East award with a potential value of $261K, currently held by Greer Laboratories, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W91YTZ-23-F-0184?
W91YTZ-23-F-0184 is the dashed form of PIID W91YTZ23F0184 (- allergen extract vaccine), held by Greer Laboratories, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W91YTZ23F0184?
W40m Mrco East awarded W91YTZ23F0184 to Greer Laboratories, Inc (potential $261K).
Who is the incumbent on W91YTZ23F0184?
Greer Laboratories, Inc is the incumbent. The current period of performance ends Jun 30, 2023.
When does Greer Laboratories, Inc’s W91YTZ23F0184 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.